Biosafety Management Based Upon Risk Assessment and Monitoring: Perspectives from a Clinical Laboratory, China
Qizhi Diao,Yongpei Long,Fangyu Yang,Cuihui Nong,Huamiao Tang,Xiangmin Zhou,Guoqiang Zhu,Qiang Ding
DOI: https://doi.org/10.2147/rmhp.s476005
2024-09-27
Risk Management and Healthcare Policy
Abstract:Qizhi Diao, 1 Yongpei Long, 2 Fangyu Yang, 3 Cuihui Nong, 1 Huamiao Tang, 1 Xiangmin Zhou, 1 Guoqiang Zhu, 4 Qiang Ding 5 1 Hainan Branch, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Sanya, People's Republic of China; 2 Department of Laboratory Medicine, The People's Hospital of Jianyang City, Sichuan, People's Republic of China; 3 Department of Clinical Laboratory Medicine, University-Town Hospital of Chongqing Medical University, Chongqing, People's Republic of China; 4 Chong Qing King Med Center for Clinical Laboratory Co., Ltd, Chongqing, People's Republic of China; 5 The Sixth People's Hospital of Chongqing, Chongqing, People's Republic of China Correspondence: Guoqiang Zhu; Qiang Ding, Email ; Background and Objective: Inadequate risk assessment and a lack of risk monitoring are common deficiencies in clinical laboratory, and are also the main causes of biosafety incidents. Therefore, we summarized the experience of implementing adequate risk assessment and maintaining risk monitoring, and established a procedure for continuously improving biosafety management. Methods: Learning from our laboratory's experience in implementing risk assessment, risk response, and risk monitoring before and during the COVID-19 epidemic, we summarized the procedures for fully identifying risks, accurately evaluating risks, maintaining risk monitoring, establishing and regular reviewing safety indicators. On this basis, we established a system for continuously improving biosafety management through risk monitoring and reviewing safety indicator. Results: We identified a total of 30 unacceptable risks prior to the COVID-19 pandemic, and developed and implemented appropriate risk control measures. After risk control, residual risks were acceptable, and no biosafety incidents have occurred. During the COVID-19 pandemic, after multiple risk monitoring, we identified ten new risks, three ineffective risk control measures, and multiple control measures for excessive protection. Then, we timely adjusted risk control measures to avoid laboratory personnel infection and excessive protection. Meanwhile, We established eight safety indicators and identified two improvement opportunities through regular reviews. Conclusion: Adequate risk identification and accurate risk assessment are particularly important for effectively controlling biosafety risks. Biosafety management should be continuously improved to deal with ineffective and excessive protection caused by various changes in experimental activities. Continuous improvement of biosafety management can be achieved through risk monitoring, regular review of safety indicators, and management reviews. This study will help laboratory managers to fully and accurately assess risks, as well as update risks and their control measures through risk monitoring, and the continuous improvement procedure established in the study has certain reference value for laboratories to effectively respond to emerging infectious diseases and avoid excessive protection. Keywords: risk assessment, risk monitoring, management review, continuous improvement, biosafety management Risk assessment is the foundation of managing biosafety. Biosafety risks are associated with factors such as personnel, safety facilities or equipment, operating processes, disinfectants, experimental waste, emergency plans, etc. However, response measures are only developed and implemented for risks that exceed the acceptable limits of the laboratory. Therefore, accurately assessing the hazard degree of risks is crucial for developing appropriate risk response measures or avoiding excessive protection. 1 However, many institutional biosafety committees (IBC) only focused on the risks associated with operation processes, and the risk evaluation was also relatively superficial, which led to inadequate risk identification and inappropriate risk response measures. In addition, biosafety management should be a continuous improvement process based on risk monitoring and review of biosafety indicators. Risk monitoring is of great significance in identifying unidentified risks, improving risk response measures, avoiding excessive protection, and responding to emerging infectious diseases. 1 The factors that determine the risk-hazard degree in clinical laboratories include the types of pathogens that may be exposed and their biological characteristics (such as virulence, transmission ability, and transmission routes), operating procedures, and sample types. Once any factor changes, using the initial risk-response measures will inevitably lead to excessive protection -Abstract Truncated-
health care sciences & services,health policy & services